Targeted Nanotechnology from Bench to Bedside

Torre, L.A.; Siegel, R.L.; Jemal, A. Lung Cancer Statistics. Adv. Exp. Med. Biol., 2016, 893, 1-19.

(a) Zaric, B.; Stojsic, V.; Carapic, V.; Kovacevic, T.; Stojanovic, G.; Panjkovic, M.; Kioumis, I.; Darwiche, K.; Zarogoulidis, K.; Stratakos, G.; Tsavlis, D.; Hohenforst-Schmidt, W.; Pitsiou, G.; Zissimopoulos, A.; Sachpekidis, N.; Karapantzos, I.; Karapantzou, C.; Zarogoulidis, P.; Perin, B. Radial Endobronchial Ultrasound (EBUS) guided suction catheter-biopsy in histological diagnosis of peripheral pulmonary lesions. J. Cancer, 2016, 7(1), 7-13.
(b) Oezkan, F.; Khan, A.; Zarogoulidis, P.; Hohenforst-Schmidt, W.; Theegarten, D.; Yasufuku, K.; Nakajima, T.; Freitag, L.; Darwiche, K. Efficient utilization of EBUS-TBNA samples for both diagnosis and molecular analyses. OncoTargets Ther., 2014, 7, 2061-2065.

(a) Zaric, B.; Stojsic, V.; Sarcev, T.; Stojanovic, G.; Carapic, V.; Perin, B.; Zarogoulidis, P.; Darwiche, K.; Tsakiridis, K.; Karapantzos, I.; Kesisis, G.; Kougioumtzi, I.; Katsikogiannis, N.; Machairiotis, N.; Stylianaki, A.; Foroulis, C.N.; Zarogoulidis, K. Advanced bronchoscopic techniques in diagnosis and staging of lung cancer. J. Thorac. Dis., 2013, 5(Suppl. 4), S359-S370.
(b) Breda, A.; Territo, A.; Guttilla, A.; Sanguedolce, F.; Manfredi, M.; Quaresima, L.; Gaya, J.M.; Algaba, F.; Palou, J.; Villavicencio, H. Correlation between confocal laser endomicroscopy (Cellvizio®) and histological grading of upper tract urothelial carcinoma: a step forward for a better selection of patients suitable for conservative management. Eur. Urol. Focus, 2017.

(a) Garg, P.K.; Deo, S.V.; Kumar, R.; Shukla, N.K.; Thulkar, S.; Gogia, A.; Sharma, D.N.; Mathur, S.R. Staging PET-CT scanning provides superior detection of lymph nodes and distant metastases than traditional imaging in locally advanced breast cancer. World J. Surg., 2016, 40(8), 2036-2042.
(b) De Vos, N.; Goethals, I.; Ceelen, W. Clinical value of (18)F-FDG- PET-CT in the preoperative staging of peritoneal carcinomatosis from colorectal origin. Acta Chir. Belg., 2014, 114(6), 370-375.
(c) Staniuk, T.; Malkowski, B.; Srutek, E.; Szlezak, P.; Zegarski, W. Comparison of FLT-PET/CT and CECT in gastric cancer diagnosis. Abdom. Radiol., 2016, 41(7), 1349-1356.
(d) Liam, C.K.; Andarini, S.; Lee, P.; Ho, J.C.; Chau, N.Q.; Tscheikuna, J. Lung cancer staging now and in the future. Respirology, 2015, 20(4), 526-534.

(a) Zarogoulidis, K.; Zarogoulidis, P.; Darwiche, K.; Boutsikou, E.; Machairiotis, N.; Tsakiridis, K.; Katsikogiannis, N.; Kougioumtzi, I.; Karapantzos, I.; Huang, H.; Spyratos, D. Treatment of non-small cell lung cancer (NSCLC). J. Thorac. Dis., 2013, 5(Suppl. 4), S389-S396.
(b) Antonakis, P.T.; Ashrafian, H.; Isla, A.M. Laparoscopic gastric surgery for cancer: where do we stand? World J. Gastroenterol., 2014, 20(39), 14280-14291.

(a) Tsoulos, N.; Papadopoulou, E.; Metaxa-Mariatou, V.; Tsaousis, G.; Efstathiadou, C.; Tounta, G.; Scapeti, A.; Bourkoula, E.; Zarogoulidis, P.; Pentheroudakis, G.; Kakolyris, S.; Boukovinas, I.; Papakotoulas, P.; Athanasiadis, E.; Floros, T.; Koumarianou, A.; Barbounis, V.; Dinischiotu, A.; Nasioulas, G. Tumor molecular profiling of NSCLC patients using next generation sequencing. Oncol. Rep., 2017, 38(6), 3419-3429.
(b) Domvri, K.; Zarogoulidis, P.; Darwiche, K.; Browning, R.F.; Li, Q.; Turner, J.F.; Kioumis, I.; Spyratos, D.; Porpodis, K.; Papaiwannou, A.; Tsiouda, T.; Freitag, L.; Zarogoulidis, K. Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. J. Cancer, 2013, 4(9), 736-754.
(c) Zarogoulidis, P.; Papadopoulos, V.; Maragouli, E.; Papatsibas, G.; Karapantzos, I.; Bai, C.; Huang, H. Tumor heterogenicity: multiple needle biopsies from different lesion sites-key to successful targeted therapy and immunotherapy. Transl. Lung Cancer Res., 2018, 7(Suppl. 1), S46-S48.
(d) Zarogoulidis, P.; Papadopoulos, V.; Maragouli, E.; Papatsibas, G.; Sardeli, C.; Man, Y.G.; Bai, C.; Huang, H. Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 >/=50. Int. J. Cancer, 2018, 7(Suppl. 1), S28-S30.

Gupta, A.; Ahmad, A.; Dar, A.I.; Khan, R. Synthetic lethality: from research to precision cancer nanomedicine. Curr. Cancer Drug Targets, 2018, 18(4), 337-346.

(a) Zarogoulidis, P.; Eleftheriadou, E.; Sapardanis, I.; Zarogoulidou, V.; Lithoxopoulou, H.; Kontakiotis, T.; Karamanos, N.; Zachariadis, G.; Mabroudi, M.; Zisimopoulos, A.; Zarogoulidis, K. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest. New Drugs, 2012, 30(4), 1628-1640.
(b) Hohenforst-Schmidt, W.; Zarogoulidis, P.; Darwiche, K.; Vogl, T.; Goldberg, E.P.; Huang, H.; Simoff, M.; Li, Q.; Browning, R.; Turner, F.J.; Le Pivert, P.; Spyratos, D.; Zarogoulidis, K.; Celikoglu, S.I.; Celikoglu, F.; Brachmann, J. Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies. Drug Des. Devel. Ther., 2013, 7, 571-583.
(c) Baliaka, A.; Zarogoulidis, P.; Domvri, K.; Hohenforst-Schmidt, W.; Sakkas, A.; Huang, H.; Le Pivert, P.; Koliakos, G.; Koliakou, E.; Kouzi-Koliakos, K.; Tsakiridis, K.; Chioti, A.; Siotou, E.; Cheva, A.; Zarogoulidis, K.; Sakkas, L. Intratumoral gene therapy versus Intravenous gene therapy for distant metastasis control with 2-diethylaminoethyl-dextran methyl methacrylate copolymer non-viral vector-p53. Gene Ther., 2014, 21(2), 158-167.

Yeo, Y.; Kim, B.K. Drug carriers: Not an innocent delivery man. AAPS J., 2015, 17(5), 1096-1104.

Du, A.W.; Stenzel, M.H. Drug carriers for the delivery of therapeutic peptides. Biomacromolecules, 2014, 15(4), 1097-1114.